<DOC>
	<DOCNO>NCT02202005</DOCNO>
	<brief_summary>The objective steady state pivotal study compare rate extent absorption evaluate Bioequivalence test drug compare approve reference product HIV infect individual</brief_summary>
	<brief_title>Multiple Dose BE Study With Nevirapine 400mg PR Tablets</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<criteria>1 . Signed date write informed consent prior admission study 2 . HIV1 infect male females 18 65 year , nonsmoker ( use cannabis may accept ) 3 . Body weight ≥ 50.0 kg BMI ≥ 18.0 ≤ 32.0 kg/m2 4 . Absence clinically significant history neurological , endocrinal , cardiovascular , pulmonary , haematological , psychiatric , gastrointestinal , renal , hepatic , obstructive disorder , cholestasis , metabolic disease 5 . Treatment stable nevirapine base combination regimen least precede 12 week ( 6 week switch antiretroviral regimen contain two nucleoside analogue efavirenz ) 6 . Background HIV therapy stable antiretroviral regimen recommend combination nevirapine accord British HIV Association clinical guideline : 1 . Abacavir lamivudine { ABC/3TC } fix dose combination Kivexa 2 . Tenofovir emtricitabine { TDF/FTC } Truvada 3 . Zidovudine lamivudine { AZT/3TC } Combivir , OR 4 . Tenofovir lamivudine separately prescribed component keep constant ( combination dosage ) throughout whole course study 7 . An HIV viral load &lt; 50 copies/mL precede 3 month screen 8 . A CD4+ Tcell count &gt; 50 cell/mm3 9 . Acceptable screen laboratory value indicate adequate baseline organ function 10 . Willingness abstain ingest medication list contraindicated nevirapine whole course study 11 . Capable complete patient diary 12 . Capable willing come back PK assessment follow 13 . Willingness refrain excessive physical activity trial 14 . Willingness male study participant father child throughout study . To prevent pregnancy female partner , male study participant female partner need take appropriate contraceptive prevent pregnancy study . 1 . Infection HIV2 HIV1 group O . 2 . Current treatment HIV protease inhibitor 3 . Participation study within 30 day Day 1 , intention participate another study participation study . 4 . Male female patient willing use male female condom prevent HIV transmission 5 . Female patient childbearing potential : 1 . Have positive serum pregnancy test screening . 2 . Are breast feed . 3 . Are plan become pregnant 4 . Are willing take appropriate measure prevent pregnancy study 6 . Females use acceptable contraceptive regimen confirm total abstinence allow participate study consider childbearing potential 7 . Laboratory parameter &gt; DAIDS grade 2 Coagulation 8 . Laboratory parameter &gt; DAIDS grade 2 Total triglyceride 9 . Hypersensitivity active substance ingredient test reference investigational product chemically related compound . 10 . Contraindication Nevirapine 11 . Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion 12 . Use concomitant medication ( stable background antiretroviral HIV therapy ) may interfere pharmacokinetics nevirapine and/or background antiretroviral HIV therapy ) 13 . Intake product contain St. John 's Wort 14 day treatment study medication ( Day 1 ) willing abstain throughout study last study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>